Read More

Ikena Oncology Refocuses on Key Programs: Analysts Maintain Outperform Ratings Amid Strategic Organizational Changes

Ikena Oncology optimizes resources for targeted oncology programs IK-930 & IK-595. Clinical updates expected H2 2024. Workforce reduced by 35%. Financially secure with $175M cash. Strategic focus on key developments in 2024.

BMY

Read More

Heart Devices Focused Silk Road Medical Stock Gets an Upgrade – Analyst Says New CEO’s Initiatives Sets Stage For ‘Back On Track’

Stifel's upgraded outlook on Silk Road Medical as CEO Chas McKhann addresses concerns, unveils a compelling vision, and outlines strategic initiatives. Analysts upgrade to Buy with $20 price target, citing confidence in TCAR technology and long-term growth under McKhann's leadership.

SILK